GlobeNewswire

Apricus Biosciences Announces Scheduling of Vitaros(TM) End-of-Review Meeting with FDA

Del

Meeting Scheduled for April 12, 2018

SAN DIEGO, March 26, 2018 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that its end-of-review meeting with the U.S. Food and Drug Administration ("FDA") to discuss the New Drug Application ("NDA") for Vitaros(TM) (alprostadil, DDAIP.HCl), a topical cream for the treatment of erectile dysfunction, is now scheduled to be held on April 12, 2018.

The FDA previously issued a Complete Response Letter ("CRL") for the Vitaros NDA, indicating that the FDA could not approve the NDA for Vitaros in its present form, identifying deficiencies related to Chemistry, Manufacturing and Control and certain safety concerns specific to the 2.5% concentration of DDAIP.HCl contained in the current formulation.

"We are looking forward to our end-of-review meeting with the FDA.  We intend to further clarify the deficiencies raised in the CRL and the information that may be needed to resolve such deficiencies and to assess the path forward for further development and a potential approval of Vitaros," stated Richard W. Pascoe, Chief Executive Officer.  "Following receipt of the end-of-review meeting minutes, we intend to update the market on our future plans for Vitaros."

About Apricus Biosciences, Inc.

Apricus Biosciences, Inc. (APRI) is a biopharmaceutical company advancing innovative medicines in urology and rheumatology. Apricus has two product candidates: Vitaros, a product candidate in the United States for the treatment of erectile dysfunction, which is in-licensed from Warner Chilcott Company, Inc., now a subsidiary of Allergan plc (Allergan); and RayVa, a product candidate which has completed a Phase 2a clinical trial for the treatment of the circulatory disorder Raynaud's phenomenon, secondary to scleroderma, for which Apricus owns worldwide rights.

For further information on Apricus, visit http://www.apricusbio.com.

Vitaros(TM) is Apricus' trademark in the United States, which is pending registration and subject to the agreement with Allergan.  Vitaros® is a registered trademark of Ferring International Center S.A. in certain countries outside of the United States.  RayVa(TM) is Apricus' trademark, which is registered in certain countries throughout the world and pending registration in the United States.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act, as amended. Statements in this press release that are not purely historical are forward-looking statements. Such forward-looking statements include, among other things: the timing of the occurrence of the end-of-review meeting with the FDA; the timing of any clinical and non-clinical studies to address the FDA's concerns and whether the results of such studies would be sufficient to overcome the deficiencies raised in the CRL; and the timing and results of Apricus' evaluation on the path forward for Vitaros. Actual results could differ from those projected in any forward-looking statements due to a variety of reasons that are outside of Apricus' control, including, but not limited to: Apricus' financial position and need for additional capital to fund its operations, which may be adversely impacted if Apricus is unable to maintain the continued listing of its common stock on the Nasdaq stock market; Apricus' ability to address any conditions for approvability of Vitaros raised by the FDA in the CRL; the risks of any additional adverse safety or other data arising from the sales and use of Vitaros in certain countries in Europe and elsewhere; competition in the ED market; and other risks identified by Apricus in its reports filed with the Securities and Exchange Commission (SEC). These forward-looking statements are made as of the date of this press release, and Apricus assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Readers are urged to read the risk factors set forth in Apricus' most recent annual report on Form 10-K, subsequent quarterly reports filed on Form 10-Q, and other filings made with the SEC. Copies of these reports are available from the SEC's website at www.sec.gov or without charge from Apricus.

CONTACT:     
Matthew Beck
mbeck@troutgroup.com
Solebury Trout
(646) 378-2933




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Apricus Biosciences, Inc. via Globenewswire

Om GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Følg saker fra GlobeNewswire

Registrer deg med din epostadresse under for å få de nyeste sakene fra GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra GlobeNewswire

Cority Recognized by Independent Analyst Firm as a “Powerhouse Vendor” – Moving Up Once Again as a Leader in The Green Quadrant EHS Software 201926.3.2019 15:10:00 CETPressemelding

Toronto, ON, March 26, 2019 (GLOBE NEWSWIRE) -- Cority, the most trusted provider of environmental, health, safety, and quality (EHSQ) software, today announced it has been recognized as an Environmental, Health, and Safety (EHS) software Leader for the third consecutive year in the latest benchmark report by independent research firm Verdantix. The Green Quadrant EHS Software 2019 provides a detailed fact-based comparison of the 23 most prominent EHS software vendors in the industry. Based on the proprietary Verdantix Green Quadrant methodology, Cority moved up the Leaders’ quadrant significantly, placing among the top vendor scores on its software application capabilities and market momentum. The results underscore Cority’s solid position in a differentiated top-tier of enterprise-scale vendors. “Cority has established itself as an enterprise-scale EHS information management powerhouse vendor,” said Yaowen Ma, Senior Analyst, Verdantix. “Cority should be shortlisted by buyers seeking

Retail Inkjet Solutions (RIS) and Boulanger are testing the InkCenter® ink cartridge refill service at Boulanger stores26.3.2019 14:12:00 CETPressemelding

CARLSBAD, Calif., March 26, 2019 (GLOBE NEWSWIRE) -- Retail Inkjet Solutions (RIS), in partnership with Boulanger, today announced a new pilot program of its ink cartridge refill service at several Boulanger retail stores. Over time, all customers of Boulanger, who specialize in home appliances and multimedia equipment, including personal and office printers, will be able to leave their empty inkjet cartridges at the Ink Bar of their local Boulanger store. While they do their shopping, a Boulanger expert advisor will refill the cartridges using the RIS InkCenter® machine, which guarantees high-quality refilling, far cheaper than buying a new cartridge. As part of this new, innovative partnership, “Ink Bars” have already opened at the following Boulanger stores: Gennevilliers, Lyon, Noyelles-Godault, Toulouse, and Toulon. “Value for money and product quality are very important for all consumers. The RIS-powered ink cartridge refill solution delivers exceptional quality ink, much more af

Wasabi Introduces Media Innovation Cloud Alliance To Deliver Disruptive Best-of-Breed Media Processing Price/Performance for Media & Entertainment26.3.2019 14:00:00 CETPressemelding

Next-Generation Multi-Vendor Cloud Solution Optimized For Movie/TV Production And Long-Term Archival Storage Boston, MA, March 26, 2019 (GLOBE NEWSWIRE) -- Wasabi, the hot cloud storage company, announces the Media Innovation Cloud Alliance, a coalition of best-of-breed media technology companies integrating across multiple clouds to deliver a price/performance ratio vastly superior to first-generation cloud providers like Amazon Web Services, Microsoft Azure and Google Cloud Platform. The mission of alliance partners is to enable media companies to affordably leverage independent, next-generation cloud services as an alternative to monolithic first-generation cloud stacks. Services offered by the Alliance span the media lifecycle from content transfer and ingest, to editing and transformation, to playback and delivery, through archiving and library management. Founding Media Innovation Cloud Alliance partners include: Acembly (multi-cloud management) Archiware (backup and archive) Cin

Wildflower Brands Inc. (CSE: SUN) (OTCQB: WLDFF) Featured in NetworkNewsWire Publication on Soaring Hemp-Based CBD Industry26.3.2019 13:30:00 CETPressemelding

NEW YORK, March 26, 2019 (GLOBE NEWSWIRE) -- via NetworkWire -- NetworkNewsWire ("NNW"), a multifaceted financial news and publishing company, today announces the publication of an editorial featuring Wildflower Brands Inc. (CSE: SUN) (OTCQB: WLDFF) . To read the full editorial discussing CBD industry forecasts following the passage of the Farm Bill, visit: http://nnw.fm/Q5q5a Hemp is making a comeback thanks to the growing popularity of cannabidiol (CBD), an active ingredient found in many forms of cannabis. It’s an ingredient that companies such as Wildflower Brands Inc. (CSE: SUN) (OTCQB: WLDFF) , a creator of plant-based health and wellness products, have been making extensive use of in recent years. The Farm Bill has been driven in large part by the growing demand for CBD. An obscure and seldom discussed chemical a decade ago, CBD has emerged as an important consumer product. … Identified as a chemical with great potential for health and wellness, CBD has started to be marketed in

Bhang Corporation’s Scott Van Rixel and Jamie Pearson Named to High Times' Most Influential People in Cannabis26.3.2019 11:00:00 CETPressemelding

LOS ANGELES, March 26, 2019 (GLOBE NEWSWIRE) -- Bhang Corporation ("Bhang" or the "Company"), the global cannabis house of brands with an extensive, award-winning portfolio of products, is proud to announce that Bhang CEO Scott Van Rixel and COO Jamie Pearson have each been recognized by High Times Magazine for their work in the cannabis industry. Scott Van Rixel has been named to the 2018 High Times’ List of 100 Most Influential People in the Cannabis Industry and Jamie Pearson has been named one of the 2018 High Times Women of Weed, Most Influential Women in Cannabis List. “We are honored to receive these accolades from High Times” said Scott Van Rixel, CEO of Bhang. “When I started Bhang 9 years ago, I did it with the goal of creating quality and consistent products that consumers love. Today, we are one of the most recognized cannabis brand houses on the planet and I thank all our employees who work tirelessly each day to make this possible.” "I am proud to lead a passionate, execu

Nasdaq, Inc. Prices €600 Million Senior Notes Offering25.3.2019 20:07:00 CETPressemelding

NEW YORK, March 25, 2019 (GLOBE NEWSWIRE) -- Nasdaq, Inc. (the “Company”) (Nasdaq: NDAQ) today announced that it priced a public offering of €600,000,000 aggregate principal amount of 1.75% senior notes due 2029 (the “Offering”). The Company expects to use the net proceeds from the Offering to refinance indebtedness and for other general corporate purposes. J.P. Morgan Securities plc, Merrill Lynch International, Mizuho International plc and Skandinaviska Enskilda Banken AB (publ) are acting as joint book-running managers for the Offering. HSBC Bank plc, ICBC Standard Bank Plc, Nordea Bank Abp, The Toronto-Dominion Bank and Wells Fargo Securities International Limited are acting as co-managers for the Offering. The Offering is being made pursuant to an effective shelf registration statement, previously filed by the Company with the U.S. Securities and Exchange Commission (the “SEC”). Before investing, you should read the prospectus supplement and accompanying prospectus, as well as oth